Pricing Log in Create free account

Coherus Oncology, Inc. (CHRS) vs Minerva Neurosciences, Inc (NERV)

Coherus Oncology, Inc. and Minerva Neurosciences, Inc are both Biotechnology companies. Coherus Oncology, Inc. and Minerva Neurosciences, Inc are of similar size ($115.7M and $109.8M). Minerva Neurosciences, Inc has the higher net margin (0.00% vs −259.4%) and the higher return on invested capital (0.00% vs 0.00%). Across the 13 metrics below, Minerva Neurosciences, Inc leads on 7 and Coherus Oncology, Inc. on 6.

Valuation

Metric CHRS NERV Biotechnology median
P/E n/m n/m 10.60
P/S 2.34 n/m 9.40
P/B 1.96 n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 4.44 n/m 9.02
Earnings yield (133.77%) (1,172.31%) (32.88%)
Free cash flow yield (156.84%) (23.31%) (23.13%)

Profitability

Metric CHRS NERV Biotechnology median
Gross margin 68.94% 0.00% 68.51%
Operating margin (311.56%) 0.00% 0.00%
Net margin (259.41%) 0.00% 0.00%
Free cash flow margin (365.22%) 0.00% 0.00%
Return on equity (146.27%) 322.05% (51.96%)
Return on assets (41.90%) (629.71%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CHRS NERV Biotechnology median
Revenue growth (TTM) 61.00% — 6.76%
EPS growth (last fiscal year) 472.00% (18,347.37%) 29.88%
Revenue growth, 5-year CAGR (38.41%) — 9.75%
Net income growth, 5-year CAGR 4.91% 0.00% 0.00%

Health

Metric CHRS NERV Biotechnology median
Debt to equity 0.61 0.00 0.00
Current ratio 1.77 20.14 4.97
Net debt to EBITDA 0.76 5.46 1.01

Dividend

Metric CHRS NERV Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CHRS NERV Biotechnology median
Market cap 115.71m 109.82m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack